Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer (KHBO1208)

Trial Profile

Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer (KHBO1208)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Biliary cancer; Cholangiocarcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Mar 2013 Planned End Date 1 Dec 2016 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top